90 related articles for article (PubMed ID: 27510785)
1. [ARID1A expression of SWI/SNF remodeling complex in pancreatic neuroendocrine tumor].
Zhang L; Jia CW; Lu ZH; Chen J
Zhonghua Bing Li Xue Za Zhi; 2016 Aug; 45(8):571-4. PubMed ID: 27510785
[TBL] [Abstract][Full Text] [Related]
2. Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors.
Han X; Chen W; Chen P; Zhou W; Rong Y; Lv Y; Li JA; Ji Y; Chen W; Lou W; Xu X
Pancreas; 2020 Apr; 49(4):514-523. PubMed ID: 32282764
[TBL] [Abstract][Full Text] [Related]
3. ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis.
Li ZY; Zhu SS; Chen XJ; Zhu J; Chen Q; Zhang YQ; Zhang CL; Guo TT; Zhang LM
Biochem Biophys Res Commun; 2017 Nov; 493(2):1018-1025. PubMed ID: 28942143
[TBL] [Abstract][Full Text] [Related]
4. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.
Zhang X; Zhang Y; Yang Y; Niu M; Sun S; Ji H; Ma Y; Yao G; Jiang Y; Shan M; Zhang G; Pang D
Cancer Epidemiol; 2012 Jun; 36(3):288-93. PubMed ID: 21889920
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage.
Ye J; Zhou Y; Weiser MR; Gönen M; Zhang L; Samdani T; Bacares R; DeLair D; Ivelja S; Vakiani E; Klimstra DS; Soslow RA; Shia J
Hum Pathol; 2014 Dec; 45(12):2430-6. PubMed ID: 25311944
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
7. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
Choi JY; Han HH; Kim YT; Lee JH; Kim BG; Kang S; Cho NH
Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma.
Abe H; Hayashi A; Kunita A; Sakamoto Y; Hasegawa K; Shibahara J; Kokudo N; Fukayama M
Int J Clin Exp Pathol; 2015; 8(3):2763-70. PubMed ID: 26045782
[TBL] [Abstract][Full Text] [Related]
9. Expression of Sex Determining Region Y-Box 2 and Pancreatic and Duodenal Homeobox 1 in Pancreatic Neuroendocrine Tumors.
Akiyama T; Shida T; Yoshitomi H; Takano S; Kagawa S; Shimizu H; Ohtsuka M; Kato A; Furukawa K; Miyazaki M
Pancreas; 2016 Apr; 45(4):522-7. PubMed ID: 26491904
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms.
Briest F; Wang Y; Arsenic R; Elezkurtaj S; Berg E; Greshake S; Lock AC; Hörsch D; Arnold CN; Hummel M; Siegmund B; Grabowski P
Anticancer Res; 2018 Jul; 38(7):3863-3870. PubMed ID: 29970506
[TBL] [Abstract][Full Text] [Related]
11. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder.
Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Ellis C; Driscoll T; Schoenberg MP; Bivalacqua TJ; Shih IeM; Netto GJ
Hum Pathol; 2014 Nov; 45(11):2233-9. PubMed ID: 25175170
[TBL] [Abstract][Full Text] [Related]
12. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.
Yadav R; Kakkar A; Sharma A; Malik PS; Sharma MC
Scand J Gastroenterol; 2016 Aug; 51(8):994-9. PubMed ID: 27162024
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases.
Faraj SF; Chaux A; Gonzalez-Roibon N; Munari E; Cubilla AL; Shih IeM; Netto GJ
Hum Pathol; 2015 May; 46(5):761-6. PubMed ID: 25776029
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic neuroendocrine neoplasms: Correlation between MR features and pathological tumor grades.
Jin F; Wang K; Qin TT; Li X; Guo F; Ma GN; Hu XH; Han P
J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):587-595. PubMed ID: 28786064
[TBL] [Abstract][Full Text] [Related]
15. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
[TBL] [Abstract][Full Text] [Related]
16. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
[TBL] [Abstract][Full Text] [Related]
17. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
18. [Expression and clinical significance of ARID1A in gastric cancer and paired adjacent noncancerous tissues].
Zhang X; Wang S; Liu N
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jan; 33(1):77-80. PubMed ID: 28031120
[TBL] [Abstract][Full Text] [Related]
19. ARID1A represses hepatocellular carcinoma cell proliferation and migration through lncRNA MVIH.
Cheng S; Wang L; Deng CH; Du SC; Han ZG
Biochem Biophys Res Commun; 2017 Sep; 491(1):178-182. PubMed ID: 28716731
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription.
Yan HB; Wang XF; Zhang Q; Tang ZQ; Jiang YH; Fan HZ; Sun YH; Yang PY; Liu F
Carcinogenesis; 2014 Apr; 35(4):867-76. PubMed ID: 24293408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]